Home/Filings/4/0001140361-24-009784
4//SEC Filing

Backus William A. 4

Accession 0001140361-24-009784

CIK 0000009326other

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 4:58 PM ET

Size

19.0 KB

Accession

0001140361-24-009784

Insider Transaction Report

Form 4
Period: 2024-02-23
Backus William A.
CAO and Assistant Treasurer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-02-23$84.40/sh+5,480$462,51218,394 total
  • Exercise/Conversion

    Common Stock

    2024-02-23$74.57/sh+3,700$275,90922,094 total
  • Sale

    Common Stock

    2024-02-23$156.94/sh2,477$388,74512,914 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2024-02-235,4800 total
    Exercise: $85.40Exp: 2027-02-21Common Stock (5,480 underlying)
  • Exercise/Conversion

    Stock Options (right to buy)

    2024-02-233,7000 total
    Exercise: $74.57Exp: 2028-02-15Common Stock (3,700 underlying)
  • Sale

    Common Stock

    2024-02-23$156.16/sh6,703$1,046,72415,391 total
  • Sale

    Common Stock

    2024-02-26$154.36/sh2,581$398,40810,333 total
  • Sale

    Common Stock

    2024-02-26$155.66/sh4,319$672,2846,014 total
  • Sale

    Common Stock

    2024-02-26$156.13/sh100$15,6135,914 total
Footnotes (7)
  • [F1]Exercise of fully vested non-qualified stock options.
  • [F2]This transaction was executed in multiple sales ranging from $155.4950 to $156.4825 per share, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or any security holder of the issuer full information regarding the number of shares and prices at which the transactions were affected regarding this footnote.
  • [F3]This transaction was executed in multiple sales ranging from $156.5300 to $157.1950 per share, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or any security holder of the issuer full information regarding the number of shares and prices at which the transactions were affected regarding this footnote.
  • [F4]This transaction was executed in multiple sales ranging from $154.0800 to $155.0300 per share, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or any security holder of the issuer full information regarding the number of shares and prices at which the transactions were affected regarding this footnote.
  • [F5]This transaction was executed in multiple sales ranging from $155.1300 to $156.0500 per share, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or any security holder of the issuer full information regarding the number of shares and prices at which the transactions were affected regarding this footnote.
  • [F6]Stock options that vested 20% on February 21, 2018, 40% on February 21, 2019, and 40% on February 21, 2020, and are exercisable.
  • [F7]Stock options that vested 20% on February 15, 2019, 40% on February 15, 2020, and 40% on February 15, 2021, and are exercisable.

Issuer

BALCHEM CORP

CIK 0000009326

Entity typeother

Related Parties

1
  • filerCIK 0001530884

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 4:58 PM ET
Size
19.0 KB